Engineered immune cells take on rare Muscle-Weakening disease
NCT ID NCT06359041
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 27 times
Summary
This early-stage study tests a new treatment called CABA-201 for people with generalized myasthenia gravis, a condition that causes severe muscle weakness. The therapy uses a patient's own immune cells, modified to target and destroy faulty immune cells that attack the body. The main goal is to check safety and see if it can reduce symptoms, though long-term medication may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS (GMG) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baylor College of Medicine Neurology Department
Houston, Texas, 77030, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Columbia University
New York, New York, 10032, United States
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Mayo Clinic - Rochester
Rochester, Minnesota, 55905, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Swedish Neuroscience Research
Seattle, Washington, 98122, United States
-
UC Davis, Department of Neurology
Sacramento, California, 95817, United States
-
University of California Irvine
Orange, California, 92868, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Massachusetts Chan Medical School
Worcester, Massachusetts, 01655, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.